Tag: Biotechnology News
Tom Oxley to Keynote the 2024 Bioelectronic Medicine Forum in New York City | National News
NEW YORK, N.Y., March 19, 2024 (SEND2PRESS NEWSWIRE) -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024. The one-day event will be held at the New York Academy of Medicine in Manhattan.
Divergent CRO Announces Launch of New Contract Research Organization | National News
ATLANTA, Ga., Feb. 1, 2024 (SEND2PRESS NEWSWIRE) -- Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.
BioAustinCTX Adds Cindy WalkerPeach and Ryan Hawkins to the Board of Directors | National News
AUSTIN, Texas, Feb. 1, 2024 (SEND2PRESS NEWSWIRE) -- BioAustinCTX, Central Texas' Life Science industry organization, announced today the appointment of Cindy WalkerPeach, PhD and Ryan Hawkins to its Board of Directors. BioAustinCTX is a nonprofit organization based in Austin, Texas focused on advancing the life science industry in the Central Texas Region.
Emerging Neurotech Startups to Present at the 2023 Neurotech Leaders Forum in San Francisco
SAN FRANCISCO, Calif. /California Newswire/ -- Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that several promising neurotechnology startups and early-stage firms will present at the 2023 Neurotech Leaders Forum in San Francisco, November 6-7. The 23rd annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.
Neo-Bionica Appoints Uli Gommel As CTO in U.S.
LOS ANGELES, Calif. /California Newswire/ -- Neo-Bionica, a leading innovator in the field of medical device development and manufacturing, is thrilled to announce the appointment of Uli Gommel as its new Chief Technology Officer (CTO). Uli will lead Neo-Bionica's technology division spearheading its mission to revolutionize the way that companies bring novel neurotechnologies and smart MedTech devices to market.
Award-winning universal vaccine method calls for deeper scientific exploration – The Slammer Method
CHESAPEAKE, Va., May 19, 2023 (SEND2PRESS NEWSWIRE) -- A new universal vaccine method developed by Eric Kikkert is outlined in an article he wrote called: "The Slammer Method: How to create effective vaccines." It recently appeared in the "Journal of Infectious Diseases and Therapy" and is proposed to work in not just humans, but animals too. The material was presented at the 2023 12th International Conference for Tropical Medicine and Infectious Disease in London, received an award and established as a universal method to create effective vaccines.
Helen Mayberg to Keynote 2023 Bioelectronic Medicine Forum in New York City
NEW YORK, N.Y., March 7, 2023 (SEND2PRESS NEWSWIRE) -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Sixth Annual Bioelectronic Medicine Forum will take place on April 4, 2023. The one-day event will be held at the New York Academy of Medicine in Manhattan.
The BioBuilder Educational Foundation Initiates Plan to Train Bioeconomy Workforce
NEWTON, Mass., Jan. 24, 2023 (SEND2PRESS NEWSWIRE) -- The BioBuilder Educational Foundation, Inc. ("BioBuilder"), which has a decade of empowering teachers and schools to bring synthetic biology education to school districts in 47 states, today announced its launch of a strategic planning process designed to grow the bioeconomy workforce at scale in urban, rural, and tribal communities.
BioBuilder and K2 Scientific Bring Synthetic Biology Programs and Laboratory Equipment to High-Need High Schools Around the Country
BOSTON, Mass., Nov. 18, 2022 (SEND2PRESS NEWSWIRE) -- As a world-recognized program that trains the next generation of innovators and skilled workers in synthetic biology, the BioBuilder Educational Foundation announced new work with K2 Scientific to make high quality tools and equipment for life science research widely accessible. BioBuilder has partnered with K2 Scientific, who will donate industry-grade refrigeration units to four high-need high schools participating in the BioBuilderClub this academic year.
Dosaggio™ by SottoPelle® Partners with PatientNow
SCOTTSDALE, Ariz., Oct. 18, 2022 (SEND2PRESS NEWSWIRE) -- Dosaggio™ by SottoPelle® and PatientNow announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).
Dosaggio by SottoPelle Partners with Cerbo
SCOTTSDALE, Ariz., Sept. 28, 2022 (SEND2PRESS NEWSWIRE) -- Dosaggio™ by SottoPelle® and Cerbo announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).
BioBuilder funded to expand student opportunity in rural and urban areas through its collaborative after school program
BOSTON, Mass., Sept. 20, 2022 (SEND2PRESS NEWSWIRE) -- Thanks to a two-year grant recently awarded by BioMADE, the BioBuilder Educational Foundation will expand a program that has supported thousands of high school inventors over the last decade. BioBuilder is leading the project, "Launching High School Bioengineers on their Paths to College and Careers," with funding that will bring the authentic tools and approaches for engineering biology to BioBuilderClub students nationwide in collaboration with East Tennessee State University, Ars Biotechnica, and Daicel Arbor Biosciences.
Kalyagen Announces Attendance and Speaking Engagement at 8th Annual Biohacking Conference
AUSTIN, Texas, Sept. 13, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.
Proteios Technology, Inc. Awarded $1.6 Million NIH SBIR Grant to Commercialize its Multivariate Cell Isolation Technology
SEATTLE, Wash., Sept. 8, 2022 (SEND2PRESS NEWSWIRE) -- Proteios Technology, Inc. is pleased to announce it's received a $1.6 million SBIR Phase II grant from the National Institutes of Health (NIH) to commercialize its multivariate (parallel) cell isolation technology. Grant funds will be used to extend Proteios' cell isolation kits to include up to 20 of the most common cell types currently used in cell therapy development.
Kalyagen Announces Attendance at the Fort Lauderdale Open with PGA Associate Jerrel Gill
AUSTIN, Texas, April 29, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen® is pleased to announce that it will be attending the Fort Lauderdale Open as part of its sponsorship of golf professional Jerrel Gill. The Open will be hosted at the Fort Lauderdale Country Club on May 2-3, 2022.
Kalyagen Announces Attendance at Paleo f(x) 2022 Conference
AUSTIN, Texas, April 27, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen is pleased to announce that it will be attending and hosting a booth (#121) at the upcoming Paleo f(x)™ 2022 conference to be held in Austin on April 29 - May 1. STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).
Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine
ROCHESTER, Minn., April 6, 2022 (SEND2PRESS NEWSWIRE) -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.
Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies
OKLAHOMA CITY, Okla., AUSTIN, Texas and MELBOURNE, Australia, April 6, 2022 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.
Neurosoft Bioelectronics Receives Nearly $3 Million in Funding
GENEVA, Switzerland, and NEW YORK, N.Y., April 5, 2022 (SEND2PRESS NEWSWIRE) -- Neurosoft Bioelectronics, an early-stage company developing tools for unmet needs in epilepsy and tinnitus, was awarded nearly $3 million USD, from the SERI-Funded European Innovation Council Accelerator Grant and a share of the $165,000 USD through the European Research Council Proof-of-Concept Grant.
Key Entrepreneurs to Present at 2022 Bioelectronic Medicine Forum
NEW YORK, N.Y., March 28, 2022 (SEND2PRESS NEWSWIRE) -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that founders and CEOs of several promising bioelectronic medicine startups will present at the Fifth Annual Bioelectric Medicine Forum on April 5, 2022. The event will take place in New York City, although participation via Zoom videoconference will be accommodated.
Kalyagen Announces Supporting Partnership of Two South Florida PGA Events and PGA Associate Jerrel Gill
AUSTIN, Texas, March 10, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen® is pleased to announce that it is a supporting partner of two upcoming South Florida PGA Section events and golf professional Jerrel Gill. The two events are the South Florida PGA Foundation PGA HOPE Classic on May 12, 2022 and the South Florida Open on June 21-23, 2022.
Pure Transplant Solutions, LLC and Vall d’Hebron University Hospital Announce Research Collaboration
AUSTIN, Texas and BARCELONA, Spain, Feb. 15, 2022 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.
Pure Transplant Solutions, LLC and Oxford Immunotec, Ltd. Announce Exclusive Sublicense Agreement to Support Commercialization of Novel B Cell Measurement Assay...
AUSTIN, Texas and OXFORD, U.K., Dec. 7, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D.
Neurotech Reports Announces Launch of BioElectRx Business Report, Serving Bioelectronic Medicine Industry
SAN FRANCISCO, Calif. /California Newswire/ -- Neurotech Reports, the San Francisco, California publisher of market intelligence for the healthcare industry, announced the launch of a new monthly newsletter covering the bioelectronic medicine industry, one of the newest and fastest growing industry segments. The publication, BioElectRx Business Report, is the first industry newsletter devoted to bioelectronic medicine.
Kalyagen™ Announces Registration of STEMREGEN® in Spain, CEO at Madrid Stem Cell Symposium
AUSTIN, Texas, Oct. 12, 2021 (SEND2PRESS NEWSWIRE) -- Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau's, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.
iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal
STONY BROOK, N.Y., Sept. 10, 2021 (SEND2PRESS NEWSWIRE) -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.
Vyriad, Inc. Appoints Harry Hoffman to its Board of Directors
ROCHESTER, Minn., Aug. 24, 2021 (SEND2PRESS NEWSWIRE) -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company's board of directors.
KROST CPAs Acts as Financial Advisor for Integrity Bio in Sale to Curia
LOS ANGELES, Calif. /California Newswire/ -- Integrity Bio, Inc., a privately held formulation and fill-finish organization, was sold to Curia (formerly Albany Molecular Research, Inc. (AMRI)), a Contract Development and Manufacturing Organization (CDMO) and leading global provider of advanced contract research, development, and manufacturing solutions. KROST, a Los Angeles-based firm, acted as the exclusive financial advisor to Integrity Bio in the transaction.
Pure Transplant Solutions, LLC Announces Research Collaboration with the Department of Surgery at the University of Cambridge
AUSTIN, Texas and CAMBRIDGE, U.K., July 21, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The University of Cambridge Abdominal Transplant Centre at Addenbrooke's Hospital.
BioAustin Appoints New Leadership and Unveils An Expanded Strategic Focus In Central Texas As BioAustinCTX
AUSTIN, Texas, June 3, 2021 (SEND2PRESS NEWSWIRE) -- Life Science industry organization BioAustin today announced changes to its leadership team, brand positioning, and long-term strategy focused on facilitating the continued growth of the life science industry in Central Texas. Over the past several years, Austin and the Central Texas region have developed into one of the fastest-growing life science hubs in the U.S.
Pure MHC, LLC Announces Launch of Contract Research Service Division and Initial Collaboration Project with argenx
AUSTIN, Texas, March 31, 2021 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.
Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection
AUSTIN, Texas and LOOS, France, March 24, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Innobiochips (IBC).
Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens in Transplant...
AUSTIN, Texas and EVANSTON, Ill., March 17, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Northwestern University, a world leader in HLA DQ antigen research.
Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health
AUSTIN, Texas, March 16, 2021 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.
Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients
AUSTIN, Texas and BIRMINGHAM, Ala., March 11, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research.
Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with...
AUSTIN, Texas and LONDON, England, Feb. 24, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King's College London.
Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of...
AUSTIN, Texas and OKLAHOMA CITY, Okla., Feb. 23, 2021 (SEND2PRESS NEWSWIRE) -- Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.
Flightpath Biosciences Launches via Illumina Accelerator: Will Conduct Largest Clinical Biomarker Study in Lyme Disease
BERKELEY, Calif. /California Newswire/ -- Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator's second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).
Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of...
AUSTIN, Texas and OKLAHOMA CITY, Okla., Feb. 4, 2021 (SEND2PRESS NEWSWIRE) -- Pure Protein, LLC (Pure Protein) and subsidiary company Pure Transplant Solutions, LLC (PTS), announced today that Blake Harlan has been promoted to President and Rico Buchli, PhD to Vice President of Products and Services.
Pure Transplant Solutions, LLC and University Hospital Basel Announce Research Collaboration
AUSTIN, Texas and BASEL, Switzerland, Jan. 27, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The Transplantation Immunology & Nephrology Department of the University Hospital of Basel.
Microcide Announces Launch of Speed-breaker for Fast Moving COVID-19 Infections for Health Care Facilities
STERLING HEIGHTS, Mich., Jan. 4, 2021 (SEND2PRESS NEWSWIRE) -- Microcide® Inc. a leading Michigan based biotechnology company, today announced the test results of its COVID-19 faster virus killing range of products, PRO-SAN® Cleaner sanitizer, SILKY-SOFT® hand sanitizer, and DENTORAL® mouthwash.
Synthetic Biology for Tennessee Schools: BioBuilder Partners with Niswonger Foundation on $8.8M Federal Grant for STEM Education
CAMBRIDGE, Mass., Dec. 29, 2020 (SEND2PRESS NEWSWIRE) -- The BioBuilder Educational Foundation announced that they are to partner with the Niswonger Foundation on their award of an "Education Innovation and Research" (EIR) Grant from the U.S. Department of Education that will focus on educational opportunities in Science, Technology, Engineering and Mathematics (STEM).
Pure Protein, LLC Announces New Website Now Offering Its HLA Reagents and Technical Services to Researchers
OKLAHOMA CITY, Okla. and AUSTIN, Texas, Nov. 30, 2020 (SEND2PRESS NEWSWIRE) -- Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), is proud to announce the launch of its new website.
Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act...
AUSTIN, Texas, Nov. 17, 2020 (SEND2PRESS NEWSWIRE) -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.
Avila Herbals Announces Manufacturing and Research and Development Agreements with Phoenix Biotechnology
CHRISTIANSBURG, Va., Oct. 28, 2020 (SEND2PRESS NEWSWIRE) -- Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology.
Biotech Firm, Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020
VENTURA, Calif. /California Newswire/ -- The American College of Gastroenterology (ACG) named Progenabiome "Outstanding Poster Presenter" for its poster: "Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection," which will be presented virtually at the ACG Annual Scientific Meeting this week.
Pure Protein, LLC to Exhibit and Preview New Website at the American Society for Histocompatibility and Immunogenetics (ASHI) 46th Annual Meeting
OKLAHOMA CITY, Okla. and AUSTIN, Texas, Oct. 15, 2020 (SEND2PRESS NEWSWIRE) -- Pure Protein, LLC (Pure Protein) an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA), announced today that it will be an exhibitor at the ASHI VIRTUAL ANNUAL MEETING, October 19 - 21, 2020.
Zeblok Computational Announces Partnership with Laufer Center and CEWIT – COVID-19 Drug Discovery
STONY BROOK, N.Y., July 20, 2020 (SEND2PRESSN NEWSWIRE) -- Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok's secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster.
ROKiT Pharma Pre-clinical Studies Show Tremendous Promise for Naturally Derived Cancer Drug, ROK-001
LOS ANGELES, Calif. /California Newswire/ -- ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.
Bay Area Lyme Foundation announces Lyme Disease Biobank Expands Into San Diego
SAN DIEGO, Calif. /California Newswire/ -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the opening of the San Diego collection site of the Bay Area Lyme Foundation's Lyme Disease Biobank, which is the first program to provide researchers with blood and urine samples from people with early Lyme disease from multiple endemic regions across the country.
